Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levetiracetam - GlaxoSmithKline/Otsuka Pharmaceuticals/UCB

Drug Profile

Levetiracetam - GlaxoSmithKline/Otsuka Pharmaceuticals/UCB

Alternative Names: E Keppra; E Keppra Dry syrup 50%; EKeppra; Keppra; Keppra XR; L-059; Levetiracetam IR; Levetiracetam XR; SIB-S1; UCB-059; UCB-22059; UCB-L059

Latest Information Update: 15 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCB
  • Developer Ache Laboratories; GlaxoSmithKline; Otsuka Pharmaceutical; UCB
  • Class Acetamides; Antidementias; Antiepileptic drugs; Neuroprotectants; Nootropics; Pyrrolidinones; Small molecules
  • Mechanism of Action SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy; Myoclonic epilepsies; Partial epilepsies; Tonic-clonic epilepsy
  • Discontinued Anxiety disorders; Neuropathic pain; Parkinsonian disorders

Most Recent Events

  • 11 Mar 2019 UCB and Otsuka Pharmaceuticals will not renew the co-development and co-promotion agreement for levetiracetam in Japan
  • 05 Jun 2018 UCB Pharma withdraws a phase II trial in Seizures in USA (IV) (NCT00627133)
  • 30 Nov 2017 Phase-III clinical trials in Partial epilepsies (Adjunctive treatment, In children, In infants, Monotherapy) in Japan (IV) (NCT03340064)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top